Blue Light Cystoscopy With Cysview® Registry
a study on Bladder Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Sima Porten, MD, MPH
Description
Summary
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Details
Data will be captured on specific patient types undergoing Blue Light Cystoscopy with Cysview for known or suspected non-muscle invasive bladder cancer. Specific clinical questions will be asked.
- What is the incremental detection rate with Blue Light Cystoscopy with Cysview over conventional white light cystoscopy in each of the seven (7) patient populations? Does this translate into lower recurrence/progression rate?
- How do the six (6) tumor variables used in the European Association of Urology (EAU) risk tables (primary/secondary, recurrence rate, size, multifocality, grade, and history of carcinoma in situ (CIS))6 affect this incremental rate?
- How does an abnormal cytology or positive or negative fluorescent in situ hybridization (FISH) affect the likelihood that Blue Light Cystoscopy with Cysview will detect more cancers than white light?
- What are the performance characteristics of Blue Light Cystoscopy with Cysview within eight (8) weeks of Bacillus Calmette-Guérin (BCG) with respect to improved tumor detection and false positive rate compared to conventional white light cystoscopy?
- What is the incremental Blue Light Cystoscopy with Cysview detection rate over random bladder biopsies alone in patients being evaluated for routine three month restaging (group 4) or occult disease (group 5)?
- What are the performance characteristics of Blue Light Cystoscopy with Cysview after repeated Blue Light Cystoscopy with Cysview evaluations with respect to improved tumor detection, false positive rate and safety compared to conventional white light?
- Does an abnormal urinalysis help identify patients with inflammation more likely to have false positive Blue Light Cystoscopy with Cysview results?
- What is the practical learning curve for becoming "proficient" with Blue Light Cystoscopy with Cysview?
- What is the overall false positive rate with Blue Light Cystoscopy with Cysview?
- Can Blue Light Cystoscopy with Cysview make the resection more complete? If yes, is this due to improved margins and/or additional tumors seen under blue light?
The Blue Light Cystoscopy with Cysview Registry is a web-based program supported by Global Vision Technologies. Data will be captured longitudinally over five (5) years on patients from each enrolled site. Each center will enter their respective site's patient data electronically.
Keywords
Bladder Cancer Cysview Hexaminolevulinate Hexvix NMIBC BLCC Blue Light Cystoscopy with Cysview Cystoscopy TURBT TUR Fluorescent cystoscopy Non-muscle invasive bladder cancer (NMIBC) Transurethral resection (TUR) Urinary Bladder Neoplasms Aminolevulinic Acid Hexaminolevulinate hydrochloride (HCL) Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Eligibility
You can join if…
Open to people ages 18 years and up
- Adult >18 years old
- Suspected or known non-muscle invasive bladder cancer on the basis of a prior cystoscopy
You CAN'T join if...
- Porphyria
- Gross hematuria
- Known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives
Locations
- University of California, San Francisco
accepting new patients
San Francisco California 94143 United States - VA Palo Alto Health Care System
accepting new patients
Palo Alto California 94304 United States
Lead Scientist at UCSF
- Sima Porten, MD, MPH
Assistant Professor, Urology. Authored (or co-authored) 53 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Photocure
- ID
- NCT02660645
- Study Type
- Observational [Patient Registry]
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02660645.